脱发障碍(脱发)

Elisabetta Muttoni, Susan Holmes
{"title":"脱发障碍(脱发)","authors":"Elisabetta Muttoni,&nbsp;Susan Holmes","doi":"10.1016/j.mpmed.2025.04.017","DOIUrl":null,"url":null,"abstract":"<div><div>This article focuses on hair loss disorders (alopecias). Hair loss can be broadly classified into scarring and non-scarring. Taking a tailored clinical history and performing a detailed examination helps guide the physician to the diagnosis. A scalp biopsy can be indicated, particularly when scarring hair loss is suspected. The aim of treatment is to prevent or slow further hair loss and promote hair regrowth where possible. Hair loss can be a cause of significant emotional and psychological distress, and it is important for this aspect of alopecia to be recognized and acknowledged. However, as treatment options can be limited, it is important to be realistic about what can be achieved therapeutically. The recent approval by the UK National Institute for Health and Care Excellence and Scottish Medicines Consortium of the Janus kinase inhibitor ritlecitinib for severe alopecia areata in patients aged ≥12 years represents a major therapeutic advance in the treatment of this difficult to manage condition.</div></div>","PeriodicalId":74157,"journal":{"name":"Medicine (Abingdon, England : UK ed.)","volume":"53 7","pages":"Pages 472-475"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hair loss disorders (alopecias)\",\"authors\":\"Elisabetta Muttoni,&nbsp;Susan Holmes\",\"doi\":\"10.1016/j.mpmed.2025.04.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>This article focuses on hair loss disorders (alopecias). Hair loss can be broadly classified into scarring and non-scarring. Taking a tailored clinical history and performing a detailed examination helps guide the physician to the diagnosis. A scalp biopsy can be indicated, particularly when scarring hair loss is suspected. The aim of treatment is to prevent or slow further hair loss and promote hair regrowth where possible. Hair loss can be a cause of significant emotional and psychological distress, and it is important for this aspect of alopecia to be recognized and acknowledged. However, as treatment options can be limited, it is important to be realistic about what can be achieved therapeutically. The recent approval by the UK National Institute for Health and Care Excellence and Scottish Medicines Consortium of the Janus kinase inhibitor ritlecitinib for severe alopecia areata in patients aged ≥12 years represents a major therapeutic advance in the treatment of this difficult to manage condition.</div></div>\",\"PeriodicalId\":74157,\"journal\":{\"name\":\"Medicine (Abingdon, England : UK ed.)\",\"volume\":\"53 7\",\"pages\":\"Pages 472-475\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicine (Abingdon, England : UK ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1357303925001069\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicine (Abingdon, England : UK ed.)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1357303925001069","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

这篇文章的重点是脱发障碍(脱发)。脱发大致可分为疤痕性和非疤痕性。量身定制的临床病史和进行详细的检查有助于指导医生做出诊断。当怀疑有瘢痕性脱发时,可进行头皮活检。治疗的目的是防止或减缓进一步的脱发,并在可能的地方促进头发再生。脱发可能会导致严重的情绪和心理困扰,认识和承认脱发的这一方面是很重要的。然而,由于治疗选择可能是有限的,重要的是要现实的什么可以实现治疗。英国国家健康与护理卓越研究所和苏格兰医药协会最近批准Janus激酶抑制剂ritlecitinib用于治疗≥12岁的严重斑秃患者,这是治疗这种难以控制的疾病的重大进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hair loss disorders (alopecias)
This article focuses on hair loss disorders (alopecias). Hair loss can be broadly classified into scarring and non-scarring. Taking a tailored clinical history and performing a detailed examination helps guide the physician to the diagnosis. A scalp biopsy can be indicated, particularly when scarring hair loss is suspected. The aim of treatment is to prevent or slow further hair loss and promote hair regrowth where possible. Hair loss can be a cause of significant emotional and psychological distress, and it is important for this aspect of alopecia to be recognized and acknowledged. However, as treatment options can be limited, it is important to be realistic about what can be achieved therapeutically. The recent approval by the UK National Institute for Health and Care Excellence and Scottish Medicines Consortium of the Janus kinase inhibitor ritlecitinib for severe alopecia areata in patients aged ≥12 years represents a major therapeutic advance in the treatment of this difficult to manage condition.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信